Low dose hydrochlorothiazide monotherapy reduced mean daytime ambulatory blood pressure from 159/105 to 145/97 mm Hg (P<0.005), with only 32% of patients achieving blood pressure control.
p-value: p=<0.005
The efficacy of low dose (12.5 to 25 mg daily) hydrochlorothiazide (HCTZ) was evaluated by ambulatory blood pressure monitoring (ABPM) in 19 mild to moderate hypertensive (mean daytime 12-h diastolic BP > or = 90 mm Hg and < 115 mm Hg) South African black patients. After a 3-week placebo run-in period, HCTZ was administered for 8 weeks as monotherapy. The mean daytime ABPM was reduced from 159 +/- 13/105 +/- 6 to 145 +/- 11/97 +/- 10 mm Hg (P < .005). Only 6/19 (32%) patients achieved BP control. The 24-h BP load fell from 69% at baseline, to 53% with 12.5 mg HCTZ and to 47% with 25 mg HCTZ daily. There were no side effects but the increase of HCTZ to 25 mg daily was followed by adverse changes (P < .05) in serum potassium levels. It is concluded that low dose of HCTZ monotherapy has only a moderate effect on the BP control and 24-h BP load while the higher 25 mg dose is associated with significant decrease in serum potassium level.
Skoularigis et al. (Sun,) conducted a other in mild to moderate hypertension (n=19). hydrochlorothiazide (HCTZ) vs. baseline was evaluated on mean daytime ambulatory blood pressure (p=<0.005). Low dose hydrochlorothiazide monotherapy reduced mean daytime ambulatory blood pressure from 159/105 to 145/97 mm Hg (P<0.005), with only 32% of patients achieving blood pressure control.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: